Randomized phase II trial of combined chemoradiation [gemcitabine + radiotherapy] with epidermal growth factor receptor (EGFR) antagonist cetuximab versus combined chemoradiation with EGFR antagonist cetuximab and sequential cetuximab for patients with locally advanced pancreatic adenocarcinoma

Trial Profile

Randomized phase II trial of combined chemoradiation [gemcitabine + radiotherapy] with epidermal growth factor receptor (EGFR) antagonist cetuximab versus combined chemoradiation with EGFR antagonist cetuximab and sequential cetuximab for patients with locally advanced pancreatic adenocarcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2008

At a glance

  • Drugs Cetuximab; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PARC
  • Most Recent Events

    • 13 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top